Sulpiride-Quetiapine

From Psychiatrienet
Revision as of 08:57, 17 August 2009 by Verena (talk | contribs) (Created page with '{{Drugswitch | from = Sulpiride | to = Quetiapine | stop = {{StopStand}} | start = {{StartStand}} | info = {{caveQT}} | view = Switchstandaardup en down.jpg }}')
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Sulpiride
Type Antipsychotic
Group Atypical AP
links
PubChem 5355
PubMed Sulpiride
Kompas (Dutch) Sulpiride
Wikipedia Sulpiride
Quetiapine
Type antipsychotic
Group atypical AP
Other use moodstabilizer
links
ATC-code N05AH04
Medscape Quetiapine
PubChem 5002
PubMed Quetiapine
Drugs.com quetiapine-fumarate
Kompas (Dutch) Quetiapine
Wikipedia Quetiapine

Switch medication from Sulpiride to Quetiapine.[5] [6]

Nietinrijdenbord.png Stop Sulpiride
  • Day 1-4: approx. 75% of initial dose
  • Day 5-8: approx. 50% of initial dose
  • Day 9-12: approx. 25% of initial dose
  • Day 13: stop
Eenrichtingbord.png Start Quetiapine
  • Day 1-4: approx. 25% of target dose
  • Day 5-8: approx. 50% of target dose
  • Day 9-12: approx. 75% of target dose
  • Day 13: target dose
Infobord.png More information
  • During this switch you could monitor ECG, especially in patients prone to QT-conduction problems.
  • There is a possibility of QT interval prolongation.[7]
    Switchstandaardup en down.jpg
Nietinrijdenbord.png — Sulpiride
Eenrichtingbord.png — Quetiapine


  1. 1.0 1.1 1.2 KNMP; Informatorium Medicamentorum 2023; Monografie "quetiapine" (Dutch)
  2. NVZA; Toxicology.org; Monografie 73 (dutch)
  3. Woods SW Chlorpromazine equivalent doses for the newer atypical antipsychotics J Clin Psychiatry 2003;64:663-667
  4. Drugs.com quetiapine-fumarate
  5. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  6. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  7. Stöllberger C, Huber JO, Finsterer J, Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005 Sep;20(5):243-51.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.